22919440|t|Induction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E).
22919440|a|In Alzheimer's disease, lipid alterations point towards peroxisomal dysfunctions. Indeed, a cortical accumulation of saturated very long chain fatty acids (VLCFAs: C22:0, C24:0, C26:0), substrates for peroxisomal beta-oxidation, has been found in Alzheimer patients. This study was realized to investigate the effects of VLCFAs at the mitochondrial level since mitochondrial dysfunctions play crucial roles in neurodegeneration. On human neuronal SK-NB-E cells treated with C22:0, C24:0, or C26:0 (0.1-20 muM; 48 h), an inhibition of cell growth and mitochondrial dysfunctions were observed by cell counting with trypan blue, MTT assay, and measurement of mitochondrial transmembrane potential (Deltapsi(m)) with DiOC(6)(3). A stimulation of oxidative stress was observed with DHE and MitoSOX used to quantify superoxide anion production on whole cells and at the mitochondrial level, respectively. With C24:0 and C26:0, by Western blotting, lower levels of mitochondrial complexes III and IV were detected. After staining with MitoTracker and by transmission electron microscopy used to study mitochondrial topography, mass and morphology, major changes were detected in VLCFAs treated-cells: modification of the cytoplasmic distribution of mitochondria, presence of large mitochondria, enhancement of the mitochondrial mass. Thus, VLCFAs can be potential risk factors contributing to neurodegeneration by inducing neuronal damages via mitochondrial dysfunctions.
22919440	76	98	long chain fatty acids	Chemical	-
22919440	100	105	C22:0	Chemical	MESH:C007547
22919440	107	112	C24:0	Chemical	-
22919440	117	122	C26:0	Chemical	MESH:C017364
22919440	132	137	human	Species	9606
22919440	154	161	SK-NB-E	CellLine	CVCL:0068
22919440	167	186	Alzheimer's disease	Disease	MESH:D000544
22919440	188	193	lipid	Chemical	MESH:D008055
22919440	220	244	peroxisomal dysfunctions	Disease	MESH:D018901
22919440	281	318	saturated very long chain fatty acids	Chemical	-
22919440	320	326	VLCFAs	Chemical	MESH:C017364
22919440	328	333	C22:0	Chemical	MESH:C007547
22919440	335	340	C24:0	Chemical	-
22919440	342	347	C26:0	Chemical	MESH:C017364
22919440	411	420	Alzheimer	Disease	MESH:D000544
22919440	421	429	patients	Species	9606
22919440	485	491	VLCFAs	Chemical	MESH:C017364
22919440	525	551	mitochondrial dysfunctions	Disease	MESH:D028361
22919440	574	591	neurodegeneration	Disease	MESH:D019636
22919440	596	601	human	Species	9606
22919440	611	618	SK-NB-E	CellLine	CVCL:0068
22919440	638	643	C22:0	Chemical	MESH:C007547
22919440	645	650	C24:0	Chemical	-
22919440	655	660	C26:0	Chemical	MESH:C017364
22919440	714	740	mitochondrial dysfunctions	Disease	MESH:D028361
22919440	777	788	trypan blue	Chemical	MESH:D014343
22919440	790	793	MTT	Chemical	MESH:C070243
22919440	877	887	DiOC(6)(3)	Chemical	MESH:C007392
22919440	941	944	DHE	Chemical	-
22919440	949	956	MitoSOX	Chemical	MESH:C521281
22919440	974	990	superoxide anion	Chemical	MESH:D013481
22919440	1068	1073	C24:0	Chemical	-
22919440	1078	1083	C26:0	Chemical	MESH:C017364
22919440	1146	1156	III and IV	Disease	MESH:D006011
22919440	1336	1342	VLCFAs	Chemical	MESH:C017364
22919440	1497	1503	VLCFAs	Chemical	MESH:C017364
22919440	1550	1567	neurodegeneration	Disease	MESH:D019636
22919440	1580	1596	neuronal damages	Disease	MESH:D009410
22919440	1601	1627	mitochondrial dysfunctions	Disease	MESH:D028361
22919440	Association	MESH:C007547	MESH:D000544
22919440	Positive_Correlation	MESH:C017364	MESH:D028361
22919440	Association	MESH:D008055	MESH:D018901
22919440	Positive_Correlation	MESH:C017364	MESH:D009410
22919440	Negative_Correlation	MESH:C017364	MESH:D006011
22919440	Positive_Correlation	MESH:C521281	MESH:D013481
22919440	Positive_Correlation	MESH:C017364	MESH:D019636
22919440	Association	MESH:D008055	MESH:D000544
22919440	Positive_Correlation	MESH:C007547	MESH:D028361
22919440	Association	MESH:C007392	MESH:D028361
22919440	Association	MESH:C017364	MESH:D000544

